• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of the mechanism of action of chemokines and immune mechanisms in the acquisition of cabazitaxel resistance

Research Project

Project/Area Number 21K16728
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 56030:Urology-related
Research InstitutionKanazawa University

Principal Investigator

Iwamoto Hiroaki  金沢大学, 附属病院, 助教 (90847245)

Project Period (FY) 2021-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2022: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2021: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
KeywordsCabazitaxel / CRPC / Resistant / CCL2 / Coffee / カバジタキセル / カーウェオール / カフェストール / CCR2 / 耐性化 / 前立腺癌 / 去勢抵抗性前立腺癌 / カバジタキセル耐性 / ケモカイン / 免疫機構
Outline of Research at the Start

進行前立腺癌に対してはARシグナルをブロックするADTが標準的な治療法として確立されている。しかし、数年はよく奏効するものの大部分の症例でADTが無効となり、CRPCへと進展する。CRPCに対しては新規ARシグナル標的薬やドセタキセル、カバジタキセルなどのタキサン系抗癌剤が承認されているが、最終的にいずれも治療抵抗性となる。タキサン系抗癌剤、特にカバジタキセル抵抗性となる機序はほとんどわかっていない。本研究ではケモカインとTAM、Tregに焦点を当て、CRPCがカバジタキセル抵抗性をきたす機序を解明し、新規治療戦略を構築することを目指す。

Outline of Final Research Achievements

Elucidating the mechanism by which CRPC confers resistance to cabazitaxel (CBZ) and developing novel therapeutic strategies is essential for improving the prognosis of prostate cancer patients. RNA microarray results suggest that TP53TG1, a long non-coding RNA, may be involved in the mechanism of CBZ resistance. We also found that coffee-containing anti-inflammatory substances, carweol and cafestol, have inhibitory effects on the proliferation and migration of CBZ-resistant prostate cancer cell lines. The results suggest that the elucidation of this mechanism of action may lead to the elucidation of the mechanism that leads to CBZ resistance.

Academic Significance and Societal Importance of the Research Achievements

ドセタキセル治療後のCRPCに対してカバジタキセルは生存期間を有意に延長したが、治療後増悪までの期間は高々2.8箇月と報告されている。進行性前立腺がんに対するカバジタキセルの効果は限定的であり、カバジタキセル抵抗性のメカニズムの解明が急務である。本研究の成果をさらに発展させることで、カバジタキセル耐性のメカニズムの解明につながり、進行性前立腺がんの予後改善に寄与することが期待される。

Report

(3 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • Research Products

    (3 results)

All 2023 2022 2021

All Journal Article (3 results) (of which Peer Reviewed: 2 results,  Open Access: 2 results)

  • [Journal Article] Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?2023

    • Author(s)
      NAKAGAWA RYUNOSUKE、IWAMOTO HIROAKI、NAITO RENATO、KADOMOTO SUGURU、YAEGASHI HIROSHI、KAWAGUCHI SHOHEI、NOHARA TAKAHIRO、SHIGEHARA KAZUYOSHI、IZUMI KOUJI、KADONO YOSHIFUMI、MIZOKAMI ATSUSHI
    • Journal Title

      Anticancer Research

      Volume: 43 Issue: 3 Pages: 1351-1359

    • DOI

      10.21873/anticanres.16283

    • Related Report
      2022 Annual Research Report
  • [Journal Article] Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer2022

    • Author(s)
      Iwamoto Hiroaki、Izumi Kouji、Nakagawa Ryunosuke、Toriumi Ren、Aoyama Shuhei、Kamijima Taiki、Shimada Takafumi、Kano Hiroshi、Makino Tomoyuki、Naito Renato、Kadomoto Suguru、Yaegashi Hiroshi、Kawaguchi Shohei、Nohara Takahiro、Shigehara Kazuyoshi、Kadono Yoshifumi、Mizokami Atsushi
    • Journal Title

      Biomedicines

      Volume: 10 Issue: 10 Pages: 2369-2369

    • DOI

      10.3390/biomedicines10102369

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy.2021

    • Author(s)
      Iwamoto H, Kano H, Shimada T, Naito R, Makino T, Kadomoto S, Yaegashi H, Shigehara K, Izumi K, Kadono Y, Mizokami A.
    • Journal Title

      In Vivo

      Volume: 35 Issue: 3 Pages: 1703-1709

    • DOI

      10.21873/invivo.12430

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2021-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi